Clinical Data's PGxHealth Sues Two Chemical Firms for Infringing Cardiac Stress Imaging Drug
July 21, 2010
Clinical Data's PGxHealth Sues Two Chemical Firms for Infringing Cardiac Stress Imaging Drug
PGxHealth has charged Toronto Research Chemicals and Santa Cruz Biotechnology for infringement because they both market the compound apadenoson, the primary ingredient of Stedivaze, a coronary vasodilator that PGxHealth is developing for myocardial perfusion imaging.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- SAEC and Duke Partner to ID SNPs Linked to Clozapine-Induced Agranulocytosis
February 3, 2010 / Pharmacogenomics Reporter - Clinical Data Completes Sale of Genetic, PGx Test Business to Transgenomic
December 30, 2010 / GenomeWeb Daily News - Transgenomic Scoops Up Clinical Data's Genetic Tests, PGx Products at 'Fair Price' of $15.4M
December 1, 2010 / Pharmacogenomics Reporter - Transgenomic to Acquire Clinical Data's Genetic Test Business for $15.4M
November 30, 2010 / GenomeWeb Daily News - Clinical Data Planning to Exit Genetic Testing Business to Fully Focus on Drug Development
November 17, 2010 / Pharmacogenomics Reporter